The story
Thalidomide was a sedative developed by the German firm Chemie Grünenthal and sold from 1957, under the name Contergan in West Germany, in more than 40 countries. It was marketed as safe and was also used against morning sickness in pregnant women. In 1961 it was pulled from the market after doctors linked it to a wave of babies born with severe malformations, especially missing or shortened limbs, a condition called phocomelia. More than 10,000 children were affected, and many died in infancy.
The link was made independently. In Hamburg, the pediatrician Widukind Lenz noticed the pattern and warned the company in November 1961, and the drug was withdrawn in Germany the same month. In Australia, the obstetrician William McBride wrote to the medical journal The Lancet in December 1961. Meanwhile, in the United States, Frances Kelsey, a new medical reviewer at the Food and Drug Administration, had refused to approve the drug in 1960 despite company pressure, because she found its safety data thin. That kept the drug off the American market, and President Kennedy honored her in 1962.
The harm happened because the drug was taken in a narrow window early in pregnancy, and because tests on animals and humans had not looked for birth defects. Standards at the time did not require proof of safety for the fetus. The scandal, along with later work showing the drug acts through a protein called cereblon, helped reshape drug regulation. Thalidomide itself found a second life: the FDA approved it in 1998 for a leprosy complication, and it is also used against the blood cancer multiple myeloma, under strict controls.
Why it mattered
- The United States passed the Kefauver-Harris amendments in 1962, requiring proof that drugs are effective and not just safe.
- Countries around the world strengthened drug approval systems, including requirements for testing on pregnancy and fetal safety.
- Survivors campaigned for compensation and recognition, creating foundations and legal precedents in Germany and Britain.
- The case made informed consent in clinical trials a regulatory norm.
Sources
- Thalidomide Science Museum
- thalidomide Britannica
Drafted by AI (Claude) from the sources above and checked against them by AI; no historian has reviewed this page. Spot a mistake? Suggest a correction. How pages are made
Community notes
Loading notes…